215 related articles for article (PubMed ID: 34391591)
1. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
Campochiaro C; Farina N; Tomelleri A; Ferrara R; Lazzari C; De Luca G; Bulotta A; Signorelli D; Palmisano A; Vignale D; Peretto G; Sala S; Esposito A; Garassino M; Gregorc V; Dagna L
Eur J Intern Med; 2021 Nov; 93():87-94. PubMed ID: 34391591
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
[TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
4. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
5. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
6. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
8. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.
Medina P; Jeffers KD; Trinh VA; Harvey RD
J Pharm Pract; 2020 Jun; 33(3):338-349. PubMed ID: 31694455
[TBL] [Abstract][Full Text] [Related]
9. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F; Buni M; Falohun A; Lu H; Song J; Johnson DH; Zobniw CM; Trinh VA; Awiwi MO; Tahon NH; Elsayes KM; Ludford K; Montazari EJ; Chernis J; Dimitrova M; Sandigursky S; Sparks JA; Abu-Shawer O; Rahma O; Thanarajasingam U; Zeman AM; Talukder R; Singh N; Chung SH; Grivas P; Daher M; Abudayyeh A; Osman I; Weber J; Tayar JH; Suarez-Almazor ME; Abdel-Wahab N; Diab A
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37328287
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
12. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
15. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
Kim ST; Tayar J; Trinh VA; Suarez-Almazor M; Garcia S; Hwu P; Johnson DH; Uemura M; Diab A
Ann Rheum Dis; 2017 Dec; 76(12):2061-2064. PubMed ID: 28830882
[TBL] [Abstract][Full Text] [Related]
17. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
Kijima T; Fukushima H; Kusuhara S; Tanaka H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Sakai Y; Saito K; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Clin Genitourin Cancer; 2021 Jun; 19(3):208-216.e1. PubMed ID: 32800718
[TBL] [Abstract][Full Text] [Related]
18. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
[TBL] [Abstract][Full Text] [Related]
19. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
20. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
